ClinVar Miner

Submissions for variant NM_000155.4(GALT):c.442C>T (p.Arg148Trp) (rs111033693)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
EGL Genetic Diagnostics, Eurofins Clinical Diagnostics RCV000414362 SCV000110061 pathogenic not provided 2018-05-16 criteria provided, single submitter clinical testing
GeneDx RCV000414362 SCV000491247 pathogenic not provided 2016-10-27 criteria provided, single submitter clinical testing The R148W missense variant in the GALT gene has been previously reported in patients with galactoemia (Reichardt et al. 1992; Berry et al. 2000; Bosch et al. 2005). Expression of R148W in COS cells found that it is associated with no detectable galactose-1-phosphate uridyltransferase enzyme activity (Reichardt et al. 1992). The R148W variant was not observed in approximately 6500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. R148W is a non-conservative amino acid substitution, it occurs at a position that is conserved in mammals, and in silico analysis predicts this variant is probably damaging to the protein structure/function. Furthermore, multiple missense variants at the same position (R148Q, R148G) and in nearby residues (S143L, V150L, V151A) are interpreted to be pathogenic variants associated with galactosemia, supporting the functional importance of this region of the protein. In summary, we interpret R148W to be a pathogenic variant.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000022113 SCV000919399 pathogenic Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase 2018-01-23 criteria provided, single submitter clinical testing Variant summary: The GALT c.442C>T (p.Arg148Trp) variant involves the alteration of a conserved nucleotide. 3/3 in silico tools predict a damaging outcome for this variant. This variant was found in 9/277232 control chromosomes at a frequency of 0.0000325, which does not exceed the estimated maximal expected allele frequency of a pathogenic GALT variant (0.0028868). The variant has been reported in affected individuals in the literature (Berry_2000; Bosch_2005; (Reichardt_1992; Schadewaldt_2014). A functional studies showed the variant to result in nondetectable levels of immunoreactive protein, despite normal levels of mRNA signifying unstable protein (Reichardt_1992; Schadewaldt_2014). Other variants affecting the same codon have been reported as pathogenic [c.442C>G (p.Arg148Gly), c.443G>A (p.Arg148Gly)], further supporting the functional importance of the position. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic.
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV000022113 SCV001156620 pathogenic Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase 2018-11-05 criteria provided, single submitter clinical testing The GALT c.442C>T; p.Arg148Trp variant (rs111033693) has been reported in individuals diagnosed with galactosemia, found in-trans with another GALT pathogenic variant (Boutron 2012, Reichardt 1992). Functional characterization indicates that the variant protein is unstable, resulting in a decrease in steady state levels and overall GALT activity (Reichardt 1992). Other missense variants at this position (p.Arg148Gly and p.Arg148Gln) have also been implicated in galactosemia (Facchiano 2010). The p.Arg148Trp variant is listed as pathogenic in ClinVar (Variation ID: 37359), and observed 8 times in the Genome Aggregation Database general population database (8/282890 alleles). The arginine at residue 148 is moderately conserved, and computational algorithms (PolyPhen-2, SIFT) predict that the variant is deleterious. Based on available information, the variant is classified as pathogenic. References: Boutron A et al. Mutation spectrum in the French cohort of galactosemic patients and structural simulation of 27 novel missense variations. Mol Genet Metab. 2012; 107(3):438-47. Facchiano A et al. Analysis of galactosemia-linked mutations of GALT enzyme using a computational biology approach. Protein Eng Des Sel. 2010; 23(2):103-13. Reichardt J et al. Characterization of two missense mutations in human galactose-1-phosphate uridyltransferase: different molecular mechanisms for galactosemia. Genomics. 1992; 12(3):596-600.
Invitae RCV000022113 SCV001589613 pathogenic Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase 2020-01-10 criteria provided, single submitter clinical testing This sequence change replaces arginine with tryptophan at codon 148 of the GALT protein (p.Arg148Trp). The arginine residue is moderately conserved and there is a moderate physicochemical difference between arginine and tryptophan. This variant is present in population databases (rs111033693, ExAC 0.01%). This variant has been observed in individual(s) with galactosemia (PMID: 1373122, 14518827, 22944367). In at least one individual the data is consistent with the variant being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 37359). This variant has been reported to affect GALT protein function (PMID: 1373122). This variant disrupts the p.Arg148 amino acid residue in GALT. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 15986423, 23151865, 17221873, 25936995). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
Research and Development, ARUP Laboratories RCV000022113 SCV000042791 pathogenic Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase 2012-12-04 no assertion criteria provided clinical testing Converted during submission to Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.